← Back to Home

FDA Approves First Factor XIa Inhibitor to Reduce Recurrent Stroke Risk in Certain Patients

Asundexian combined with antiplatelet therapy reduced the risk of ischemic stroke in a large trial; however, bleeding signals in older patients and early in treatment remain important considerations when weighing its benefits.

By SURL BioNews

For people who have recently experienced an ischemic stroke, preventing another event becomes a treatment priority after the acute phase. On November 9, the U.S. Food and Drug Administration (FDA) approved Bayer’s Sunharbo (asundexian), giving some patients an additional option alongside antiplatelet therapy to reduce stroke risk.

This is the first coagulation factor XIa inhibitor approved by the FDA, indicated for adults who have recently experienced a mild-to-moderate, non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. “Non-cardioembolic” means that the blood clot causing the blockage did not originate in the heart; this approval does not cover stroke prevention in patients with atrial fibrillation.

The approval was based on the phase 3 OCEANIC-STROKE trial, which enrolled 12,327 adults. The study used a randomized, double-blind design, with participants assigned to groups within 72 hours of symptom onset. Both groups received antiplatelet therapy, with either 50 milligrams of asundexian once daily or placebo added.

During follow-up with a median treatment duration of 14.2 months, the relative risk of ischemic stroke was 26% lower in the asundexian group than in the placebo group. This figure does not mean 26 fewer strokes per 100 people; the FDA announcement did not report the absolute event rates for the two groups, so it is not yet possible to use this figure to calculate how many patients would actually avoid an event.

Safety requires an assessment by subgroup and treatment period. Overall rates of major bleeding were similar between the two groups, but major bleeding was more frequent in the asundexian group among patients aged 75 and older and during the first 90 days of treatment. Gastrointestinal bleeding was also more common. This approval provides a new option for certain patients while underscoring that clinical assessments must consider differences in risk by age and treatment period, alongside overall average results.

References

  1. FDA